Literature DB >> 34988697

Is autosomal dominant polycystic kidney disease an early sweet disease?

Angélique Dachy1,2,3, Jean-Paul Decuypere1, Rudi Vennekens4, François Jouret3,5, Djalila Mekahli6,7.   

Abstract

The clinical course of autosomal dominant polycystic kidney disease (ADPKD) starts in childhood. Evidence of the beneficial impact of early nephron-protective strategies and lifestyle modifications on ADPKD prognosis is accumulating. Recent studies have described the association of overweight and obesity with rapid disease progression in adults with ADPKD. Moreover, defective glucose metabolism and metabolic reprogramming have been reported in distinct ADPKD models highlighting these pathways as potential therapeutic targets in ADPKD. Several "metabolic" approaches are currently under evaluation in adults, including ketogenic diet, food restriction, and metformin therapy. No data are available on the impact of these approaches in childhood thus far. Yet, according to World Health Organization (WHO), we are currently facing a childhood obesity crisis with an increased prevalence of overweight/obesity in the pediatric population associated with a cardio-metabolic risk profile. The present review summarizes the knowledge about the role of glucose metabolism in the pathophysiology of ADPKD and underscores the possible harm of overweight and obesity in ADPKD especially in terms of long-term cardiovascular outcomes and renal prognosis.
© 2022. The Author(s), under exclusive licence to International Pediatric Nephrology Association.

Entities:  

Keywords:  Autosomal dominant polycystic kidney disease; Children; Glucose; Insulin; Obesity; Overweight

Mesh:

Substances:

Year:  2022        PMID: 34988697     DOI: 10.1007/s00467-021-05406-z

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  72 in total

1.  Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease.

Authors:  Jacob A Torres; Samantha L Kruger; Caroline Broderick; Tselmeg Amarlkhagva; Shagun Agrawal; John R Dodam; Michal Mrug; Leslie A Lyons; Thomas Weimbs
Journal:  Cell Metab       Date:  2019-10-17       Impact factor: 27.287

2.  Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.

Authors:  Vinita Takiar; Saori Nishio; Patricia Seo-Mayer; J Darwin King; Hui Li; Li Zhang; Anil Karihaloo; Kenneth R Hallows; Stefan Somlo; Michael J Caplan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

3.  Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.

Authors:  Xueqi Wang; Suhua Zhang; Yang Liu; Daniela Spichtig; Sarika Kapoor; Hermann Koepsell; Nilufar Mohebbi; Stephan Segerer; Andreas L Serra; Daniel Rodriguez; Olivier Devuyst; Changlin Mei; Rudolf P Wüthrich
Journal:  Kidney Int       Date:  2013-05-29       Impact factor: 10.612

4.  Food Restriction Ameliorates the Development of Polycystic Kidney Disease.

Authors:  Gina Warner; Kyaw Zaw Hein; Veronica Nin; Marika Edwards; Claudia C S Chini; Katharina Hopp; Peter C Harris; Vicente E Torres; Eduardo N Chini
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

Review 5.  Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.

Authors:  Kristen L Nowak; Katharina Hopp
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-21       Impact factor: 8.237

Review 6.  Defective metabolism in polycystic kidney disease: potential for therapy and open questions.

Authors:  Isaline Rowe; Alessandra Boletta
Journal:  Nephrol Dial Transplant       Date:  2014-01-23       Impact factor: 5.992

7.  Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD).

Authors:  Ronald D Perrone; Kaleab Z Abebe; Terry J Watnick; Andrew D Althouse; Kenneth R Hallows; Christina M Lalama; Dana C Miskulin; Stephen L Seliger; Cheng Tao; Peter C Harris; Kyongtae Ty Bae
Journal:  Kidney Int       Date:  2021-06-27       Impact factor: 18.998

8.  Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

Authors:  Isaline Rowe; Marco Chiaravalli; Valeria Mannella; Valeria Ulisse; Giacomo Quilici; Monika Pema; Xuewen W Song; Hangxue Xu; Silvia Mari; Feng Qian; York Pei; Giovanna Musco; Alessandra Boletta
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

9.  Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.

Authors:  Ming-Yang Chang; Tsu-Lin Ma; Cheng-Chieh Hung; Ya-Chung Tian; Yung-Chang Chen; Chih-Wei Yang; Yi-Chuan Cheng
Journal:  Sci Rep       Date:  2017-08-02       Impact factor: 4.379

10.  Dissection of metabolic reprogramming in polycystic kidney disease reveals coordinated rewiring of bioenergetic pathways.

Authors:  Christine Podrini; Isaline Rowe; Roberto Pagliarini; Ana S H Costa; Marco Chiaravalli; Ivano Di Meo; Hyunho Kim; Gianfranco Distefano; Valeria Tiranti; Feng Qian; Diego di Bernardo; Christian Frezza; Alessandra Boletta
Journal:  Commun Biol       Date:  2018-11-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.